Inari Medical (NARI) Jefferies London Healthcare Conference 2024 summary

Strategic overview and growth drivers

• Focused on venous thromboembolism (VTE) with two purpose-built platforms for PE and DVT, treating over 165,000 patients since 2016.

• Expanding into four adjacent markets with unmet needs, leveraging similar purpose-built tools.

• International expansion underway, now in 15+ markets across Latin America and Asia-Pacific, with growing contributions.

U.S. VTE market development and penetration

• U.S. VTE market has a $6B TAM with 700,000 annual cases; only 8% currently treated with company’s platforms.

• Majority of patients still managed conservatively; early stages of shifting to catheter-based interventions.

• Long-term vision is to reach penetration rates similar to STEMI (90%+), moving away from lytic-based therapies.

Clinical evidence and impact

• PEERLESS RCT showed FlowTriever superior to catheter-directed thrombolysis (CDT) in intermediate-risk PE, with immediate patient improvement and shorter hospital stays.

• 60% lower 30-day readmission rate for FlowTriever vs. CDT; potential $150M revenue opportunity from share shift.

• Strong physician feedback and RCT-level evidence expected to accelerate adoption.

• Ongoing trials: PEERLESS II (FlowTriever vs. anticoagulation), PERSEVERE (high-risk PE), and DEFIANCE (DVT).